Loading
companiesCompany
Tyra Biosciences
Tyra Biosciences designs precise pills against a family of growth-signal proteins called FGFRs, which are faulty in some bladder, liver and bile duct cancers and in a bone growth disorder.
Overview
Tyra Biosciences is a Carlsbad, California company developing next-generation FGFR inhibitors designed to avoid resistance mutations and to spare related kinases. Its lead candidate, dabogratinib (TYRA-300), is an FGFR3-selective inhibitor in clinical development for non-muscle invasive bladder cancer and low-grade upper tract urothelial cancer, and in the phase 2 BEACH301 study in achondroplasia. TYRA-430 (FGFR4/3) is in the phase 1 SURF431 study in advanced hepatocellular carcinoma and other solid tumours, and TYRA-200 (FGFR1/2/3) is in the phase 1 SURF201 study in intrahepatic cholangiocarcinoma and other FGFR2-altered tumours. Tyra completed its Nasdaq IPO in September 2021, raising 198.7 million US dollars gross.
Headquarters
Carlsbad, CA, US
Scorecard
All companies#406of 1244 companies, score 9
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +4
0 approved, 0 in phase 3, 1 earlier, 1 targets, 4 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · 12.42 million shares at 16 US dollars including full exercise of the underwriters' option; closed 17 September 2021 | 2021 | $199M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · TYRA
Stage
Public
Website
Phase 2small molecule
TYRA-300 is an experimental small-molecule drug from Tyra Biosciences in phase 2 trials for bladder & urothelial cancer, aimed at FGFR2.
Notes
top- Founding year and later financings not sourced. Investor news pages (ir.tyra.bio) returned 403.
Similar pages
- CompanyBasilea Pharmaceutica
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, Small-molecule kinase inhibitors.
- PersonLipika Goyal
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TrialFOENIX-CCA2
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
- TrialFIRST-308
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TrialTHOR
Shares FGFR2, Bladder & urothelial cancer, Small-molecule kinase inhibitors.
- TrialFIGHT-202
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TreatmentHMPL-453
cancers
fronts
technologies
targets
drugs
Phase 2small molecule